Adolore BioTherapeutics (”Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the ...
DELRAY BEACH, FL / ACCESS Newswire / February 4, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal exc ...
According to the authors of a recent paper, "the placebo response in clinical trials has four components: regression to the mean (RTM), measurement artefacts, natural tendency (NT) of the disease, and ...
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
Among the research grants, Taimalieutu Kiwi Tamasese from The Family Centre has been awarded $80,000 in funding to lead a study on gout within Pasifika communities living in the Wellington and ...